Skip to main content
SpringerLink
Log in

Lessons Learned Since the Last Renal-Retinal Conference

  • Chapter
Diabetic Renal-Retinal Syndrome

  • 82 Accesses

Abstract

Diabetes mellitus the most prevalent cause of end-stage renal disease (ESRD) in the industrialized world. As tabulated in the United States Renal Data System (USRDS) 2001 Report, of 88,091 patients begun on therapy for ESRD during 1999, 38,160 (43%) had diabetes, an incidence rate of 83 per million population [1]. Reflecting their relatively higher death rate compared to other causes of ESRD, the prevalence of US diabetic ESRD patients on December 31, 1999, was 34% (114,478 of 340,261 patients). Both glomerulonephritis and hypertensive renal disease rank below diabetes in frequency of diagnosis among new ESRD patients, substantiating Mauer and Chavers contention that ‘Diabetes is the most important cause of ESRD in the Western world’ [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. United States Renal Data System, USRDS 2001 Annual Data Report, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, June, 2001.

    Google Scholar 

  2. Mauer SM, Chavers BM. A comparison of kidney disease in type I and type II diabetes. Adv Exp Med Biol 1985; 189: 299–303.

    PubMed  CAS  Google Scholar 

  3. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National estimates and general information on diabetes in the United States, Revised edition. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, 1998.

    Google Scholar 

  4. National Center for Health Statistics. Health, United States, 1998. Public Health Service, Hyattsville, Maryland, 1999.

    Google Scholar 

  5. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 2001; 37(2 Part 2): 722–727.

    PubMed  CAS  Google Scholar 

  6. Blohme G, Nyström L, Arnqvist HG, et al. Male predominance of type 1 (insulin-dependent) diabetes in young adults: results from a 5-year prospective nationwide study of the 15–34 age group in Sweden. Diabetologia 1993; 35: 56–62.

    Google Scholar 

  7. Polonsky KS. The β-cell in diabetes: from molecular genetics to clinical research. Diabetes 1995; 44: 705–717.

    PubMed  CAS  Google Scholar 

  8. Harris MI, Eastmen RC. Early detection of undiagnosed non-insulin-dependent diabetes mellitus. JAMA 1996; 276: 1261–1262.

    PubMed  CAS  Google Scholar 

  9. Madsbad S., McNair P, Faber OK, Binder C, Christiansen Transbol J. β-cell function and metabolic control in insulin-dependent treated diabetics. Acta Med Endocrinol 1980; 1980: 196–200.

    Google Scholar 

  10. Wahren J, Johansson B-L, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath JR. C-peptide revisited — new physiological effects and therapeutic implications. J Intern Med 1996; 240: 115–124.

    PubMed  CAS  Google Scholar 

  11. Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology — from West to the rest. Diabetes Care 1992; 15: 232–252.

    PubMed  CAS  Google Scholar 

  12. Harris M, Hadden WC, Knowles WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20–74 yr. Diabetes 1987; 36: 523–534.

    PubMed  CAS  Google Scholar 

  13. Stephens GW, Gillaspy JA, Clyne D, Mejia A, Pollak VE. Racial differences in the incidence of end-stage renal disease in Types I and II diabetes mellitus. Am J Kidney Dis 1990; 15: 562–567.

    PubMed  CAS  Google Scholar 

  14. Haffner SM, Hazuda HP, Stern MP, Patterson JK, Van-Heuven WA, Fong D. Effects of socioeconomic status on hyperglycemia and retinopathy levels in Mexican Americans with NIDDM. Diabetes Care 1989; 12: 128–134.

    PubMed  CAS  Google Scholar 

  15. National Diabetes Data Group. Diabetes in America. NIH Publication No. 85-1468, August 1985.

    Google Scholar 

  16. Council on Ethical and Judicial Affairs. Black-white disparities in health care. JAMA 1990; 163: 2344–2346.

    Google Scholar 

  17. Melton LJ, Palumbo PJ, Chu CP. Incidence of diabetes mellitus by clinical type. Diabetes Care 1983; 6: 75–86.

    PubMed  Google Scholar 

  18. Ritz E, Stefanski A. Diabetic nephropathy in Type II diabetes. Am J Kidney Dis 1996; 2: 167–194.

    Google Scholar 

  19. Sheehy MJ. HLA and insulin-dependent diabetes. A protective perspective. Diabetes 1992; 41: 123–129.

    CAS  Google Scholar 

  20. Biesenback G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994; 9: 1097–1102.

    Google Scholar 

  21. Wirta O, Pasternack A, Laippala P, Turjanmaa V. Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clinical Nephrology 1996; 45: 10–17.

    PubMed  CAS  Google Scholar 

  22. Abourizk NN, Dunn JC. Types of diabetes according to National Diabetes Data Group Classification. Limited applicability and need to revisit. Diabetes Care 1990; 13: 1120–1122.

    PubMed  CAS  Google Scholar 

  23. Sims EAH, Calles-Escandon J. Classification of diabetes. A fresh look for the 1990s? Diabetes Care 1990; 13: 1123–1127

    PubMed  CAS  Google Scholar 

  24. Berman DH, Friedman EA, Lundin AP. Aggressive ophthalmological management in diabetic ESRD: a study of 31 consecutively referred patients. Amer J Nephrol 1992; 12: 344–350.

    CAS  Google Scholar 

  25. Clark DW, Nowak TV. Diabetic gastroparesis. What to do when gastric emptying is delayed. Postgrad Med 1994; 95: 195–198, 201–204.

    PubMed  CAS  Google Scholar 

  26. Battle WM, Cohen JD, Snape WJ Jr. Disorders of colonic motility in patients with diabetes mellitus. Yale J Biol Med 1983; 56: 277–283.

    PubMed  CAS  Google Scholar 

  27. Lux G. Disorders of gastrointestinal motility — diabetes mellitus. Leber Magen Darm 1989; 19: 84–93.

    PubMed  CAS  Google Scholar 

  28. Miodovnik M, Rosenn BM, Khoury JC, Grigsby JL, Siddiqi TA. Does pregnancy increase the risk for development and progression of diabetic nephropathy? Am J Obstet Bynecol 1996; 174: 1180–1191.

    CAS  Google Scholar 

  29. Kaaja R, Sjoberg L, hellsted T, Immonenen I, Sane T, Teramo K. Long-term effects of pregnancy on diabetic complications. Diabet Med 1996; 13: 165–169.

    PubMed  CAS  Google Scholar 

  30. Meisel A. The Right to Die. John Wiley and Sons, New York, 1989, p 122.

    Google Scholar 

  31. Kjellstrand CM. Practical aspects of stopping dialysis and cultural differences. In: Kjellstrand CM, Dossetor JB (eds), Ethical Problems in Dialysis and Transplantation. Kluwer Academic Publishers, Dordrecht, 1992.

    Google Scholar 

  32. Pommer W, Bressel F, Chen F, Molzahn. There is room for improvement of preterminal care in diabetic patients with end-stage renal failure — The epidemiological evidence in Germany. Nephrol Dial Transplant 1997; 12: 1318–1230.

    PubMed  CAS  Google Scholar 

  33. Passa P. Diabetic nephropathy in the NIDDM patient on the interface between diabetology and nephrology. What do we have to improve? Nephrol Dial Transplant 1997; 12: 1316–1317.

    PubMed  CAS  Google Scholar 

  34. Cheigh J, Raghavan J, Sullivan J, Tapia L, Rubin A, Stenzel KH. Is insufficient dialysis a cause for high morbidity in diabetic patients? J Amer Soc Nephrol 1991; 317 (abstract).

    Google Scholar 

  35. Lowder GM, Perri NA, Friedman EA. Demographics, diabetes type, and degree of rehabilitation in diabetic patients on maintenance hemodialysis in Brooklyn. J Diabetic Complications 1988; 2: 218–226.

    CAS  Google Scholar 

  36. Lindblad AS, Nolph KD, Novak JW, Friedman EA. A survey of the NIH CAPD Registry population with end-stage renal disease attributed to diabetic nephropathy. J Diabetic Complications 1988; 2: 227–232.

    CAS  Google Scholar 

  37. Legrain M, Rottembourg J, Bentchikou A, et al. Dialysis treatment of insulin dependent diabetic patients. Ten years experience. Clin Nephrol 1984; 21: 72–81.

    PubMed  CAS  Google Scholar 

  38. Rubin J, Hsu H. Continuous ambulatory peritoneal dialysis: ten years at one facility. Amer J Kidney Dis 1991; 17: 165–169.

    CAS  Google Scholar 

  39. Prevention of peritonitis in CAPD. Lancet 1991; 337: 22–23.

    Google Scholar 

  40. Sutherland DER, Morrow CE, Fryd DS, Ferguson R, Simmons RL, Najarian JS. Improved patient and primary renal allograft survival in uremic diabetic recipients. Transplantation 1982; 34: 319–325.

    PubMed  CAS  Google Scholar 

  41. Sollinger HW, Ploeg RJ, Eckhoff DE, Stegall MD, Isaacs R, Pirsch JD, D’Alessandro AM, Knechtle SJ, Kalayoglu M Beizer FO. Two hundred consecutive simultaneous pancreas-kidney transplants with bladder drainage. Surgery 1993; 114: 736–743.

    PubMed  CAS  Google Scholar 

  42. Shaffer D, Simpson MA, Madras PN, Sahyoun AI, Conway PA, Davis CP, Monaco AP. Kidney transplantation in diabetic patients using cyclosporine. Five-year follow-up. Arch Surg 1995; 130: 287–288.

    Google Scholar 

  43. Robertson RP. Pancreas transplantation in humans with diabetes mellitus. Diabetes 1991; 40: 1085–1089.

    PubMed  CAS  Google Scholar 

  44. Diagnostic and therapeutic technology assessment (DATTA). Pancreatic transplantations. JAMA 1991; 265: 510–514.

    Google Scholar 

  45. Cecka JM, Terasaki PI. 1991. The UNOS Scientific Renal Transplant Registry — 1991. Clinical Transplants 1991, (Terasaki P.I. ed.) UCLA Tissue Typing Lab, Los Angeles CA, pp 1–11, 1992.

    Google Scholar 

  46. Sutherland D, Gruessner A, Moudry-Munns K. International Pancreas Transplant Registry report. Transplant Proc 1994; 26: 407–411.

    PubMed  CAS  Google Scholar 

  47. Douzdjian V, Ricd JC, Gugliuzza KK, Fish JC, Carson RW. Renal allograft and patient outcome after transplantation: Pancres-kidney versus kidney-alone transplant in Type 1 diabetic patients versus kidney-alone transplants in nondiabetic patients. Amer J Kidney Dis 1996; 27: 106–116

    CAS  Google Scholar 

  48. Manske CL, Wang Y, Thomas W. Mortality of cadaveric kidney transplantation versus combined kidney-pancreas transplantation in diabetic patients. Lancet 1995; 346: 1658–1662.

    PubMed  CAS  Google Scholar 

  49. Kennedy WR, Navarro X, Goetz FC, et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990; 322: 1031–1037.

    PubMed  CAS  Google Scholar 

  50. Ramsay RC, Goetz FC, Sutherland DE, Mauer SM, Robison LL, Cantril HL, Knobloch WH, Najarian JS. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 208–214.

    PubMed  CAS  Google Scholar 

  51. Remuzzi G, Ruggenenti P, Mauer SM. Pancreas and kidney/pancreas transplants: experimental medicine or real improvement? Lancet 1994; 353: 27–31.

    Google Scholar 

  52. Taylor RJ, Bynon JS, Stratta RJ. Kidney/pancreas transplantation: a review of the current status. Urol Clin North Am 1994; 21: 343–354.

    PubMed  CAS  Google Scholar 

  53. Brunner FP, Fassbinder W, Broyer M, Oules R, Brynger H, Rizzoni G, Challah S, Seiwood NH, Dykes SR, Wing AJ. Survival on renal replacement therapy: data from the EDTA Registry. Nephrol Dial Transplant 1988; 3: 109–122.

    PubMed  CAS  Google Scholar 

  54. Gokal R, Jakubowski C, King J, Hunt L, Bogle S, Baillod R, Marsh F, Ogg C, Oliver D, Ward M, et al. Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4-year analysis of a prospective multicentre study. Lancet 1988; 2: 1105–1109.

    Google Scholar 

  55. Charra B, VoVan C, Marcelli D, Ruffet M, Jean G, Hurot JM, Terrat JC, Vanel T, Chazot C. Diabetes mellitus in Tassin, France: remarkable transformation in incidence and outcome of ESRD in diabetes. Adv Ren Replace Ther 2001; 8: 42–56.

    PubMed  CAS  Google Scholar 

  56. Maiorca R, Cancarini G, Manili L, Brunori G, Camerini C, Strada A, Feller P. CAPD is a first class treatment: results of an eight-year experience with a comparison of patient and method survival in CAPD and hemodialysis. Clin Nephrol 1988; 30(Supp 1): S3–S7.

    PubMed  Google Scholar 

  57. Burton PR, Walls J. Selection-adjusted comparison of life-expectancy of patients on continuous ambulatory peritoneal dialysis, haemodialysis, and renal transplantation. Lancet 1987; 1: 1115–1119.

    PubMed  CAS  Google Scholar 

  58. Tzamaloukas AH, Murata GH, Malhotra D. Renal clearances in continuous ambulatory peritoneal dialysis: differences between diabetic and non-diabetic subjects. Int J Artif Organsr 2001; 24: 203–207.

    CAS  Google Scholar 

  59. US Renal Data System, USRDS 1997 Annual Data Report, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, April 1997.

    Google Scholar 

  60. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed), Evaluation of Chemotherapeutic Agents. Columbia University Press, New York, 1949, pp 191–205.

    Google Scholar 

  61. Carlson DM, Johnson WJ, Kjellstrand CM. Functional status of patients with end-stage renal disease. Mayo Clin Proc 1987; 62: 338–344.

    PubMed  CAS  Google Scholar 

  62. Gutman RA, Stead WW, Robinson RR. Physical activity and employment status of patients on maintenance dialysis. N Engl J Med 1981; 304: 309–313.

    PubMed  CAS  Google Scholar 

  63. Ifudu O, Paul H, Mayers JD, Cohen LS, Brezsynyak WF, Herman AI, Avram MM, Friedman EA. Pervasive failed rehabilitation in center-based maintenance hemodialysis patients. Am J Kidney Die 1994; 23: 394–400.

    CAS  Google Scholar 

  64. Ifudu O, Mayers J, Matthew J, Tan CC, Cambridge A, Friedman EA. Dismal rehabilitation in geriatric inner-city hemodialysis patients. JAMA 1994; 271: 29–33.

    PubMed  CAS  Google Scholar 

  65. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, Steffes MW, Striker GE. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Amer J Kidney Dis 1995; 25: 107–112.

    CAS  Google Scholar 

  66. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Ann Intern Med 1996; 156: 286–289.

    CAS  Google Scholar 

  67. Sawicki PT, Dahne R, Bender R, Berger M. Prolonged QT interval as a predictor of mortality in diabetic nephropathy. Diabetologia 1996; 39: 77–81.

    PubMed  CAS  Google Scholar 

  68. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med, 1993, 328: 1676–1682.

    PubMed  CAS  Google Scholar 

  69. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 1626–1632.

    PubMed  CAS  Google Scholar 

  70. Robison WG Jr, Tillis TN, Laver N, Kinoshita JH. Diabetes-related of the rat retina prevented with an aldose inhibitor. Exp Eye Res 1990; 50: 355–366.

    PubMed  CAS  Google Scholar 

  71. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Internat 1995; 47: 1703–1720.

    Google Scholar 

  72. Solerte SB, Fioravanti M, Patti AL, Schifino N, Zanoletti MG, Inglese V, Ferrari E. Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta Diabetol Lat 1987; 24:229–239.

    PubMed  CAS  Google Scholar 

  73. Solerte SB, Ferrari E. Diabetic retinal vascular complications and erythrocyte filterability; results of a 2-year follow-up study with pentoxifylline. 1985; 4: 341–350.

    CAS  Google Scholar 

  74. Chaiken RL, Palmisano J, Norton ME, Banerji MA, Bard M, Sachimechi I, Lebovitz HE. Interaction of hypertension and diabetes on renal function in black NIDDM subjects. Kidney Internat 1995; 47: 1697–1702.

    CAS  Google Scholar 

  75. Christlieb AR. Treatment selection considerations for the hypertensive diabetic patient. Arch Intern Med 1990; 150: 1167–1174.

    PubMed  CAS  Google Scholar 

  76. Keane WF, Shapiro BE. Renal protective effects of angiotensin-converting enzyme inhibition. Am J Cardiol 1990; 65: 491–591.

    Google Scholar 

  77. Siegel EG. Normoglycemia as a therapy goal in diabetes treatment — concept and realization. Klin Wochenschr 1990; 68: 306–312.

    PubMed  CAS  Google Scholar 

  78. Euclid study group. Randomised pacebo-controlled trial of lisinopril in normotensive pateints with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–1792.

    Google Scholar 

  79. Donnelly R, Molyneaux LM, Willey KA, Yue DK. Comparative effects of indapamide and Captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Am J Cardiol 1996; 77: 26B–30B.

    PubMed  CAS  Google Scholar 

  80. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996; 125: 201–204.

    PubMed  CAS  Google Scholar 

  81. Liou HH, Huang TP, Campese VM. Effect of long-term therapy with on proteinuria and renal function in with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron 1995; 69: 41–48.

    PubMed  CAS  Google Scholar 

  82. Gissen Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–1863.

    Google Scholar 

  83. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Ann Tntern Med 2001; 134: 370–379.

    Google Scholar 

  84. Mainous AG 3rd, Gill JM. The lack of screening for diabetic nephropathy: evidence from a privately insured population. Fam Med 2001; 33: 115–119.

    PubMed  Google Scholar 

  85. Sawicki PT, Muhlhauser I, Bender R, Pethke W, Heinemann L, Berger M. Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. J Intern Med 1996; 239: 345–352.

    PubMed  CAS  Google Scholar 

  86. Wang PH, Lau J, Chalmers TC. Meta-analysis intensive blood glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306–1309.

    PubMed  CAS  Google Scholar 

  87. Evanoff G, Thompson C, Brown J, Weinman. Prolonged dietary protein restriction in diabetic nephropathy. Arch Intern Med 1989; 149: 1129–1133.

    PubMed  CAS  Google Scholar 

  88. Jameel N, Pugh JA, Mitchell BD, Stern MP. Dietary protein intake is not correlated with clinical proteinuria in NIDDM. Diabetes Care 1992; 15: 178–183.

    PubMed  CAS  Google Scholar 

  89. Pedrinini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Inatern Med 1996; 124: 627–632.

    Google Scholar 

  90. Wilczek HE, Jaremko G, Tyden G, Groth CG. Evolution of diabetic nephropathy in kidney grafts. Evidence that a simultaneously transplanted pancreas exerts a protective effect. Transplantation 1995; 59: 51–57.

    PubMed  CAS  Google Scholar 

  91. Lebel M, Kingma I, Grose JH, Langlois S. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients. Amer J Hypertension 1995; 8: 545–551.

    CAS  Google Scholar 

  92. King GL, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 1994; 45: 179–188.

    PubMed  CAS  Google Scholar 

  93. Wang PH, Korc M. Searching for the Holy Grail: the cause of diabetes. Lancet 1995; 346: s4.

    PubMed  Google Scholar 

  94. Porte Jr D, Schwartz MW. Diabetes complications: Why is glucose potentially toxic? Science 1996; 272: 699–670.

    PubMed  CAS  Google Scholar 

  95. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995; 38: 387–394.

    PubMed  CAS  Google Scholar 

  96. Craven PA, Studer RK, Negrete H, DeRubertis FR. Protein kinase C in diabetic nephropathy. J Diabetes Complications 1995; 9: 241–245.

    PubMed  CAS  Google Scholar 

  97. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform bII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemie control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059–11063.

    PubMed  CAS  Google Scholar 

  98. The Diabetes Control and Complications Trial Research Group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.

    Google Scholar 

  99. Karin M. The AP-1 complex and its role in transcriptional control by protein kinase C. In: Cohen P, Foulkes JG (eds), Molecular Aspects of Cellular Regulation. Elsevier, New York, 1991, pp 235–253.

    Google Scholar 

  100. Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 1990; 9: 2241–2246.

    PubMed  CAS  Google Scholar 

  101. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest 1989; 87: 31–38.

    Google Scholar 

  102. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993; 265: E783–E793.

    PubMed  CAS  Google Scholar 

  103. Wolf BA, Williamson JR, Eamon RA, Chang K, Sherman WR, Turk J. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 1991; 87: 31–38.

    PubMed  CAS  Google Scholar 

  104. Kikkawa HM, Sugimoto T, Koya D, Araki S, Togawa M, Shigeta Y. Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J Diabetes Complications 1995; 9: 246–248.

    PubMed  Google Scholar 

  105. Ziyadeh FN, Fumo P, Rodenberger CH, Kuncio GS, Neilson EG. Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1(IV) in glomerular mesangial cells. J Diabetes Complications 1995; 4: 255–261.

    Google Scholar 

  106. Wenzel UP, Fouqueray B, Biswas P, Grandaliano G, Choudhury GG, Abboud HE. Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy. J Clin Invest 1995; 95: 1244–1252.

    PubMed  CAS  Google Scholar 

  107. Birch KA, Heath WF, Hermeling RN, Johnston CM, Stramm L, Dell C, Smith C, Williamson JR, Reifel-Miller A. LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element. Diabetes 1996; 45: 642–650.

    PubMed  CAS  Google Scholar 

  108. Ishii H, Jirouske MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, heath WF, Stramm LE, Feener EP, King GL. Amelioration of vascular dysfunction in diabeti rats by an oral PKC β2 inhibitor. Science 1996; 272: 728–731.

    PubMed  CAS  Google Scholar 

  109. Frank RN. The aldose reductase controversy. Diabetes 1994; 43: 169–172.

    PubMed  CAS  Google Scholar 

  110. Van Heyningen R. Formation of polyols by the lens of the rat with’ sugar’ cataract. Nature 1959; 184: 194–195.

    Google Scholar 

  111. Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol Sci 1994; 15: 293–297.

    PubMed  CAS  Google Scholar 

  112. Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 1994; 37: 328–330.

    PubMed  CAS  Google Scholar 

  113. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315–1321.

    PubMed  CAS  Google Scholar 

  114. Sell DR, Monnier VM. End stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990; 85: 380–384.

    PubMed  CAS  Google Scholar 

  115. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biological, and clinical implications for diabetes and aging. J Lab Invest 1994; 70: 138–151.

    CAS  Google Scholar 

  116. chimura T, Nakano K, Hashiguchi T, Iwamoto H, Miura K, Yoshimura Y, Hanyu N, Hirata K, Imakuma M, Motomiya Y, Maruyama I. Elevation of N-(carboxymethyl)valine residue in hemoglobin of diabetic patients. Its role in the development of diabetic nephropathy. Diabetes Care 2001; 24: 891–896.

    Google Scholar 

  117. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 1995; 96: 1395–1403.

    PubMed  CAS  Google Scholar 

  118. Uchimura T, Nakano K, Hashiguchi T, Iwamoto H, Miura K, Yoshimura Y, Hanyu N, Hirata K, Imakuma M, Motomiya Y, Maruyama I. Elevation of N-(carboxymethyl)valine residue in hemoglobin of diabetic patients. Its role in the development of diabetic nephropathy. Diabetes Care 2001; 24: 891–896.

    PubMed  CAS  Google Scholar 

  119. Sabbatini M. Sansone G, Uccello F, Giliberti A, Conte G, Andreucci VE. Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 1992; 42: 875–881.

    PubMed  CAS  Google Scholar 

  120. Moncado S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews 1991; 43: 109–142.

    Google Scholar 

  121. Bank N, Aynedjian HS. Tole of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 1993; 43: 1306–1312.

    PubMed  CAS  Google Scholar 

  122. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991; 87: 432–438.

    PubMed  CAS  Google Scholar 

  123. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441–9445.

    PubMed  CAS  Google Scholar 

  124. Nakamura Y, Horil Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Amer J Path 1993; 143: 1649–1656.

    PubMed  CAS  Google Scholar 

  125. Tsilbary EC, Charonis AS, Reger LA, Wohlhueter RM, Furcht LT. The effect of nonenzymatic glycosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. J Biol Chem 1988; 263: 4302–4308.

    Google Scholar 

  126. Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988; 203: 495–505.

    PubMed  CAS  Google Scholar 

  127. Way KJ, Reid JJ. Effect of aminoguanidine on the impaired nitric oxide-mediated neurotransmission in anococcygeus muscle from diabetic rats. Neuropharmacology 1994; 33: 1315–1322.

    PubMed  CAS  Google Scholar 

  128. Knowx LK, Stewart AG, Hayward PG, Morrison WA. Nitric oxide synthase inhibitors improve skin flap survival in the rat. Microsurgery 1994; 15: 708–711.

    Google Scholar 

  129. Tilton RG, Chang K, Corbett JA, Misko TP, Currie MG, Bora NS, Kaplan HJ, Williamson JR. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 1994; 35: 3278–3288.

    PubMed  CAS  Google Scholar 

  130. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90: 1110–1105.

    PubMed  CAS  Google Scholar 

  131. Wong GKT, Marsden PA. Nitric oxide synthases: regulation in disease. Nephrol Dial Transplant 1996; 11: 215–220.

    PubMed  CAS  Google Scholar 

  132. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26–29.

    PubMed  CAS  Google Scholar 

  133. Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629–1632.

    PubMed  CAS  Google Scholar 

  134. Swamy-Mruthinti S, Green K, Abraham EC. Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Experimental Eye Research 1996; 62: 505–510.

    PubMed  CAS  Google Scholar 

  135. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995; 38: 387–394.

    PubMed  CAS  Google Scholar 

  136. Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 1991; 40: 1016–1019.

    PubMed  CAS  Google Scholar 

  137. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32–35.

    PubMed  CAS  Google Scholar 

  138. Miyauchi Y, Shikama H, Takasu T, Okamiya H, Umeda M, Hirasaki E, Ohhata I, Nakayama H, Hakagawa S. Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozotocin-induced diabetic rats. European J Endocrinology 1996; 134: 467–473.

    CAS  Google Scholar 

  139. Schmidt RE, Dorsey DA, Beaudet LN, Reiser KM, Williamson JR, Tilton RG. Effect of aminoguanidine on the frequency of neuronal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozotocin-induced diabetes. Diabetes 1996; 45: 284–290.

    PubMed  CAS  Google Scholar 

  140. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93: 1905–1912.

    PubMed  CAS  Google Scholar 

  141. Archibald V, Cotter MA, Keegan A, Cameron NE. Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn-Schmiedbergs Arch Pharm 1996; 353: 584–591.

    CAS  Google Scholar 

  142. Brownlee M. Pharmacological modulation of the advanced glycosylation reaction. Prog Clin Biol Res 1989; 304: 235–248.

    PubMed  CAS  Google Scholar 

  143. Nicholls K, Mandel TE. Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. Lab Invest 1989; 60: 486–491.

    PubMed  CAS  Google Scholar 

  144. Lyons TJ, Dailie KE, Dyer DG, Dunn JA, Baynes JW. Decrease in skin collagen glycation with improved glycemie control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991; 87: 1910–1915.

    PubMed  CAS  Google Scholar 

  145. Wald H, Markowitz H, Zevin S, Popovtzer MM. Opposite effects of diabetes on nephrotoxic and ischemic acute tubular necrosis. Proc Soc Exp Biol Med 1990; 195: 51–56.

    PubMed  CAS  Google Scholar 

  146. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B. Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 1991; 40: 1328–1334.

    PubMed  CAS  Google Scholar 

  147. Makino H, Yamasaki Y, Hironaka K, Ota Z. Glomerular extracellular matrices in rat diabetic glomerulopathy by scanning electron microscopy. Virchows Arch B Cell Pathol 1992; 62: 19–24.

    CAS  Google Scholar 

  148. Petersen J, Ross J, Rabkin R. Effect of insulin therapy on established diabetic nephropathy in rats. Diabetes 1988; 37: 1346–1350.

    PubMed  CAS  Google Scholar 

  149. Stockand JD, Sansom SC. Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease. Amer j Kidney Dis 1997; 29: 971–981.

    CAS  Google Scholar 

  150. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704–11708.

    PubMed  CAS  Google Scholar 

  151. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 4: 552–556.

    Google Scholar 

  152. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, et al. Prevention of diabetic vascular dysfunction by guanidines, Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42: 221–232.

    PubMed  CAS  Google Scholar 

  153. Sensi M, Pricci F, Andreani D, DiMario U. Advanced nonenzymatic glycation endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications. Diabetes Res 1991; 16: 1–9.

    PubMed  CAS  Google Scholar 

  154. Eika B, Levin RM, Longhurst PA. Collagen and bladder function in streptozotocin-diabetic rats: effects of insulin and aminoguanidine. J Urol 1992; 148: 167–172.

    PubMed  CAS  Google Scholar 

  155. Vlassara H. Serum advanced glycosylation end products: a new class of uremic toxins? Blood Purif 1994; 12: 54–59.

    PubMed  CAS  Google Scholar 

  156. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Internat 1994; 46: 216–222.

    CAS  Google Scholar 

  157. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. New Engl J Med 1991; 325: 836–842.

    PubMed  CAS  Google Scholar 

  158. Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I, Vitella D, Diez MT, Pelaez F, Ruby C, Kendall RL, Mao X, Griffin P, Calaycay J, Zierath JR, Heck JV, Smith RG, Moller DE. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999; 284: 974–977.

    PubMed  CAS  Google Scholar 

  159. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG, Harris MI, Hadden WC, Knowles WC, Bennett PH. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704–1714.

    PubMed  CAS  Google Scholar 

  160. Schwartz RS. The new immunology — the end of immunosuppressive drug therapy? N Engl J Med 1999; 340: 754–755.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine SUNY, Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, New York, 11203

    Eli A. Friedman M.D. (Chief, Division of Renal Disease Distinguished Teaching Professor)

Authors
  1. Eli A. Friedman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Downstate Medical Center, State University of New York, New York, USA

    Eli A. Friedman M.D.

  2. Colombia University, New York, USA

    Francis A. L’Esperance Jr. M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Friedman, E.A. (2002). Lessons Learned Since the Last Renal-Retinal Conference. In: Friedman, E.A., L’Esperance, F.A. (eds) Diabetic Renal-Retinal Syndrome. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0614-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-0614-9_19

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3930-7

  • Online ISBN: 978-94-010-0614-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation